ScreenerHero

GALT Galectin Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · galectintherapeutics.com
3.620USD-3.72%Mkt Cap: 365.08M $P/E: —

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap365.08M USD
Enterprise Value512.08M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-30.84M USD
Revenue/Share—
Last Price3.620 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.24
PEG-36.15
EV/EBITDA—
EV/Revenue—
P/S—
P/B-1.79
EPS (TTM)-0.43
EPS (Forward)-1.68
52W Range
2.03031% of range7.130
52W High7.130 USD
52W Low2.030 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE24.44%
ROA-157.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.88M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-4.07%
Net Debt130.69M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity-1.06
Current Ratio0.10
Quick Ratio0.09
Book Value/Sh-2.10 USD
Cash/Share0.13 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:6
Split DateMar 23, 2012
Analyst Consensus
Rating—
Target (Mean)11.00 USD
Upside (mean)+203.9%
Target Range11.00 USD – 11.00 USD
# Analysts1
Ownership
Shares Out.100.85M
Float47.77M
Insiders53.08%
Institutions15.66%
Short Interest
Short Ratio29.1d
Short % Float12.13%
Short % Out.9.26%
Shares Short9.34M
Short (prev mo.)9.00M
Technical
SMA 503.733 (-3.0%)
SMA 2003.238 (+11.8%)
Beta0.38
S&P 52W Chg16.45%
Avg Vol (30d)304.22K
Avg Vol (10d)209.91K
Technical Indicators
RSI (14)42.8
MACD-0.0221
MACD Signal0.0254
MACD Hist.-0.0475
BB Upper4.173 USD
BB Middle3.896 USD
BB Lower3.618 USD
BB Width14.27%
ATR (14)0.2537 USD
Vol Ratio (20d)0.57x